IGC Fundamental Analysis - IGC PHARMA INC

Name: IGC PHARMA INC (IGC) Stock
Brand: IGC PHARMA INC
Rating: 4.5 (3 reviews)

Fundamental Rating

IGC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. IGC has a bad profitability rating. Also its financial health evaluation is rather negative. IGC is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IGC has reported negative net income.

IGC had a negative operating cash flow in the past year.

In the past 5 years IGC always reported negative net income.

In the past 5 years IGC always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of IGC (-79.84%) is worse than 71.88% of its industry peers.

IGC has a Return On Equity of -104.34%. This is in the lower half of the industry: IGC underperforms 61.46% of its industry peers.

		Industry Rank	Sector Rank
ROA	-79.84%
ROE	-104.34%
ROIC	N/A

ROA(3y)-93.23%

ROA(5y)-72.05%

ROE(3y)-122.42%

ROE(5y)-91.4%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IGC has a Gross Margin of 45.97%. This is in the better half of the industry: IGC outperforms 63.02% of its industry peers.

In the last couple of years the Gross Margin of IGC has grown nicely.

IGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	45.97%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.84%

GM growth 5Y75.22%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, IGC has more shares outstanding

Compared to 5 years ago, IGC has more shares outstanding

Compared to 1 year ago, IGC has a worse debt to assets ratio.

2.2 Solvency

IGC has an Altman-Z score of -12.45. This is a bad value and indicates that IGC is not financially healthy and even has some risk of bankruptcy.

IGC's Altman-Z score of -12.45 is on the low side compared to the rest of the industry. IGC is outperformed by 75.00% of its industry peers.

A Debt/Equity ratio of 0.02 indicates that IGC is not too dependend on debt financing.

The Debt to Equity ratio of IGC (0.02) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Altman-Z	-12.45

ROIC/WACCN/A

WACC8.87%

2.3 Liquidity

A Current Ratio of 1.25 indicates that IGC should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.25, IGC is doing worse than 77.08% of the companies in the same industry.

IGC has a Quick Ratio of 1.25. This is a bad value and indicates that IGC is not financially healthy enough and could expect problems in meeting its short term obligations.

IGC has a Quick ratio of 0.47. This is amonst the worse of the industry: IGC underperforms 91.15% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.25
Quick Ratio	0.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.61% over the past year.

IGC shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.07%.

The Revenue for IGC have been decreasing by -20.77% on average. This is quite bad

EPS 1Y (TTM)62.61%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.33%

Revenue 1Y (TTM)25.07%

Revenue growth 3Y47.02%

Revenue growth 5Y-20.77%

Sales Q2Q%20.59%

3.2 Future

Based on estimates for the next years, IGC will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.20% on average per year.

IGC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.74% yearly.

EPS Next Y30.18%

EPS Next 2Y10.2%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year4.61%

Revenue Next 2Y9.74%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IGC. In the last year negative earnings were reported.

Also next year IGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.2%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IGC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IGC PHARMA INC

NYSEARCA:IGC (10/31/2025, 8:04:00 PM)

After market: 0.3998 +0 (+1.14%)

0.3953

0 (-0.93%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-14 2025-08-14/amc

Earnings (Next)11-12 2025-11-12

Inst Owners18.55%

Inst Owner ChangeN/A

Ins Owners3.95%

Ins Owner Change-0.66%

Market Cap36.35M

Revenue(TTM)1.33M

Net Income(TTM)-6342000

Analysts80

Price Target3.7 (836%)

Short Float %0.33%

Short Ratio0.28

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)27.87%

Min EPS beat(2)14.05%

Max EPS beat(2)41.69%

EPS beat(4)4

Avg EPS beat(4)22%

Min EPS beat(4)8.5%

Max EPS beat(4)41.69%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)3.37%

Min Revenue beat(2)-0.38%

Max Revenue beat(2)7.13%

Revenue beat(4)3

Avg Revenue beat(4)11.44%

Min Revenue beat(4)-0.38%

Max Revenue beat(4)38.04%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-6.45%

PT rev (3m)-6.45%

EPS NQ rev (1m)0%

EPS NQ rev (3m)30.21%

EPS NY rev (1m)0%

EPS NY rev (3m)35.39%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-34.21%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-10.17%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	27.39
P/FCF	N/A
P/OCF	N/A
P/B	5.98
P/tB	8.91
EV/EBITDA	N/A

EPS(TTM)-0.07

EYN/A

EPS(NY)-0.07

Fwd EYN/A

FCF(TTM)-0.05

FCFYN/A

OCF(TTM)-0.05

OCFYN/A

SpS0.01

BVpS0.07

TBVpS0.04

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-79.84%
ROE	-104.34%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	45.97%
FCFM	N/A

ROA(3y)-93.23%

ROA(5y)-72.05%

ROE(3y)-122.42%

ROE(5y)-91.4%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.84%

GM growth 5Y75.22%

F-Score3

Asset Turnover0.17

Health

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	79.23%
Cap/Sales	35.64%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.25
Quick Ratio	0.47
Altman-Z	-12.45

F-Score3

WACC8.87%

ROIC/WACCN/A

Cap/Depr(3y)84.26%

Cap/Depr(5y)139.57%

Cap/Sales(3y)48.11%

Cap/Sales(5y)101.2%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)62.61%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.33%

EPS Next Y30.18%

EPS Next 2Y10.2%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)25.07%

Revenue growth 3Y47.02%

Revenue growth 5Y-20.77%

Sales Q2Q%20.59%

Revenue Next Year4.61%

Revenue Next 2Y9.74%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y25.3%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y27.92%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y29.59%

OCF growth 3YN/A

OCF growth 5YN/A

IGC PHARMA INC / IGC FAQ

What is the fundamental rating for IGC stock?

ChartMill assigns a fundamental rating of 1 / 10 to IGC.

What is the valuation status for IGC stock?

ChartMill assigns a valuation rating of 0 / 10 to IGC PHARMA INC (IGC). This can be considered as Overvalued.

Can you provide the profitability details for IGC PHARMA INC?

IGC PHARMA INC (IGC) has a profitability rating of 1 / 10.

What is the expected EPS growth for IGC PHARMA INC (IGC) stock?

The Earnings per Share (EPS) of IGC PHARMA INC (IGC) is expected to grow by 30.18% in the next year.

IGC PHARMA INC (IGC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

IGC PHARMA INC / IGC FAQ

What is the fundamental rating for IGC stock?

What is the valuation status for IGC stock?

Can you provide the profitability details for IGC PHARMA INC?

What is the expected EPS growth for IGC PHARMA INC (IGC) stock?